We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

OMER Omeros Corporation

0.04 (1.83%)
Dec 01 2023 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 1,348,754
Bid Price 2.20
Ask Price 3.87
News -
Day High 2.23


52 Week Range


Day Low 1.965
Company Name Stock Ticker Symbol Market Type
Omeros Corporation OMER NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.04 1.83% 2.23 20:00:00
Open Price Low Price High Price Close Price Prev Close
2.16 1.965 2.23 2.23 2.19
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
5,826 1,348,754 $ 2.12 $ 2,863,465 - 0.92 - 7.7975
Last Trade Time Type Quantity Stock Price Currency
19:30:32 7 $ 2.20 USD

Omeros Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
139.56M 62.87M - 0 47.42M 0.75 2.94
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Omeros News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No OMER Message Board. Create One! See More Posts on OMER Message Board See More Message Board Posts

Historical OMER Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.832.3951.81062.08796,5100.4021.86%
1 Month1.252.3951.131.68667,3420.9878.4%
3 Months3.393.490.921.90740,023-1.16-34.22%
6 Months6.127.79750.923.50664,921-3.89-63.56%
1 Year2.157.79750.923.96711,5570.083.72%
3 Years11.6423.850.927.43801,518-9.41-80.84%
5 Years14.2025.490.929.99749,613-11.97-84.3%

Omeros Description

Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |